Friend or Foe? Decoding the Dual Role of CLEC4E in Cancer
In the complex landscape of the tumor microenvironment (TME), Tumor-Associated Macrophages (TAMs) often play a paradoxical role. While macrophages are the sentinels of our immune system, the TME frequently corrupts them, driving them toward an immunosuppressive M2-like phenotype that fosters tumor growth and resists treatment. Finding a "molecular brake" to halt this pro-tumorigenic activity has been a long-standing goal in immuno-oncology. A recent breakthrough published in Clinical and Translational Medicine offers a promising new direction: targeting the gene CLEC4E (C-type lectin domain family 4 member E) to reprogram TAMs.
The CLEC4E & TAM Connection: Targeting Immunosuppression in the TME
CLEC4E, also known as Mincle (Macrophage-inducible C-type lectin), is traditionally recognized for its role in sensing pathogens and tissue damage. However, this new research highlights its "dark side" in oncology. In the TME, CLEC4E is abnormally upregulated on TAMs. This overexpression drives TAM proliferation and downregulates antigen presentation genes, effectively creating an "immune shelter" for cancer cells. Clinical data confirms that high CLEC4E expression in CD68+ TAMs correlates significantly with poor prognosis in melanoma and ovarian cancer patients.
The Epigenetic Switch: Clinical Potential of the BRD4-CEBPβ-CLEC4E Axis
The study elucidates a novel epigenetic mechanism driving this overexpression. The researchers identified a specific signaling axis: BRD4-CEBPβ-CLEC4E.
- BRD4, a member of the BET protein family (epigenetic readers), binds to acetylated histones.
- It regulates the transcription factor CEBPβ.
- CEBPβ, in turn, promotes the transcription of CLEC4E.
Figure1. CLEC4E expression on TAMs and its impact on T cell suppression.
This pathway offers a therapeutic window. By using BET inhibitors (such as NHWD-870), researchers successfully blocked the BRD4-CEBPβ interaction. This downregulation of CLEC4E reprogrammed the TAMs, restoring their antigen-presenting capabilities and enhancing the infiltration and cytotoxicity of CD8+ T cells.
Preclinical Validation in Vivo: Myeloid-Specific Clec4e Knockout Mice
To confirm this mechanism, the research team utilized a robust validation system, including myeloid-specific Clec4eknockout mice (Lyz2-Cre driven deletion).
In both B16F10 melanoma and ID8 ovarian cancer models, mice lacking Clec4e exhibited:
- Significantly reduced tumor growth rates.
- Decreased ascites formation.
- Extended survival times.
- A shift in the TME: reduced M2-like TAMs and increased Granzyme B+ T cells.
Beyond Oncology: CLEC4E Models in Autoimmunity and Infection
While its role in cancer is a hot topic, CLEC4E remains a critical node in other therapeutic areas, making it a high-value target for broad immunological research:
Infectious Disease: Clec4e (Mincle) agonists are being explored as adjuvants. In bacterial infection models, synthetic glycolipids targeting Mincle induced potent Th1/Th17 responses. Conversely, in fungal keratitis, Mincle activation helps inhibit cell apoptosis to reduce inflammatory damage.
Autoimmunity: In Rheumatoid Arthritis (RA), Mincle expression is elevated in synovial tissue, suggesting a role in driving chronic inflammation. Similarly, in skin allergies and acute kidney injury (AKI), Mincle-dependent pathways have been shown to exacerbate tissue damage.
Cyagen CLEC4E Mouse Models: Accelerating Clinical Translation
Whether investigating epigenetic reprogramming in tumors or dissecting inflammatory pathways in autoimmune disease, the availability of reliable animal models is the bottleneck for validation.
To support researchers exploring the CLEC4E axis, Cyagen offers a comprehensive library of genetically engineered mouse models, including:
- Constitutive Knockout (KO):Clec4e KO mice (C57BL/6 background)
- Conditional Knockout (cKO):Clec4e-Flox mice (Ideal for crossing with Lyz2-Cre or Cx3cr1-Cre for myeloid/macrophage-specific studies)
These models are essential for replicating the "clinical-animal-cellular" validation loop required for high-impact publications.
Interested in targeting the TME? Follow Cyagen for more insights into the latest model organisms driving drug discovery.
Reference：
[1] Liao M, Long K, Dong L, et al. Targeting CLEC4E in immunosuppressive tumour-associated macrophages via BET inhibition. Clin Transl Med. 2025;15:e70505
[2] Lin J, He K, Zhao G, et al. Mincle inhibits neutrophils and macrophages apoptosis in A. fumigatus keratitis. Int Immunopharmacol. 2017;52:101-109. doi:10.1016/j.intimp.2017.08.006
[3] Decout A, Silva-Gomes S, Drocourt D, et al. Rational design of adjuvants targeting the C-type lectin Mincle. Proc Natl Acad Sci U S A. 2017;114(10):2675-2680. doi:10.1073/pnas.1612421114
[4] Kalantari P, Bunnell SC, Stadecker MJ. The C-type Lectin Receptor-Driven, Th17 Cell-Mediated Severe Pathology in Schistosomiasis: Not All Immune Responses to Helminth Parasites Are Th2 Dominated. Front Immunol. 2019;10:26. Published 2019 Jan 30. doi:10.3389/fimmu.2019.00026
[5] Takata K, Takano S, Miyagi M, et al. Elevated macrophage-inducible C-type lectin expression in the synovial tissue of patients with rheumatoid arthritis. Cent Eur J Immunol. 2021;46(4):470-473. doi:10.5114/ceji.2021.111471
[6] Kostarnoy AV, Gancheva PG, Lepenies B, et al. Receptor Mincle promotes skin allergies and is capable of recognizing cholesterol sulfate. Proc Natl Acad Sci U S A. 2017;114(13):E2758-E2765. doi:10.1073/pnas.1611665114
[7] Inoue T. M1 macrophage triggered by Mincle leads to a deterioration of acute kidney injury. Kidney Int. 2017;91(3):526-529. doi:10.1016/j.kint.2016.11.026
